Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.

Also called NCT03949374

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 126 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03949374
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03949374. Randomized; no masking; primary purpose treatment. Start 2015-10-23 (actual); primary completion 2018-04-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients
Condition
Hypercholesterolemia
Condition
Dyslipidemias
Intervention (Drug)
CRESTOR, reference formulation of rosuvastatin
Intervention (Drug)
ROVASRO, generic formulation of rosuvastatin
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct03949374
Content hash
ef16a3c04a259b3481fc309b6e355411e8a78d8e0fa80a54dfe177b1c9026458